Check out our latest open access publication in Critical Reviews in Oncology/Hematology!
The March edition of the FNM newsletter includes a feature on PanCareLIFE. The article describes how the paradigm in childhood oncology has changed from acute care to cure cancer to chronic care, where there is a focus on cure but also on prevention of late effects and their lifelong, informed management. Lifelong management relies on systematic research in late effects, like that conducted in PanCareLIFE, as well as sophisticated systems of care transition for adult survivors and empowering survivors to co-manage their own care through initiatives like Together to Smile in the Czech Republic.
You can read more in Czech here.
PanCareLIFE researchers at UNIBE have just published a new paper ‘Audiological monitoring in Swiss childhood cancer patients’, funded in part by PanCareLIFE.
Pediatric Blood & Cancer, 65(3) e26877, DOI: 10.1080/08880018.2017.1323985
Full audiological monitoring is the best strategy to detect hearing loss early and to provide timely intervention in the absence of a clinical method of otoprotection. Full monitoring requires audiological evaluation before, and then during and after ototoxic cancer treatment. In a worldwide context of monitoring protocols that vary substantially, we analyzed the audiological monitoring of childhood cancer patients over the last decade across treatment centers in Switzerland.
We retrospectively searched for audiological evaluations in all nine Swiss Pediatric Oncology Centers. We analyzed proportions of patients who had audiological monitoring and described type and timing of monitoring. We determined predictors of audiological monitoring using multivariable logistic regression and described time trends.
We included 185 patients from the Swiss Childhood Cancer Registry diagnosed from 2005 to 2013 who had platinum chemotherapy and/or cranial radiation ≥30 Gray and who were alive at time of study. Less than half of children, 43%, had full audiological monitoring (before, during, and after treatment), while 72% were tested after cancer treatment. Nonstudy patients were less likely to have had monitoring in all phases of cancer treatment. Patients who received treatment with cisplatin or both platinum chemotherapy and cranial radiation were more likely to have had monitoring after treatment. Monitoring during and after treatment increased over the study period, but monitoring before treatment was insufficient in all time periods.
Our population-based study indicates that audiological monitoring is insufficient in Switzerland, particularly for nonstudy patients. Clinicians must become more aware of the importance of full audiological monitoring.
PanCareLIFE researchers at EMC, VUmc, AMC, PMC and UKM have just published a new paper ‘Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors’, funded in part by PanCareLIFE.
Pediatric Hematology and Oncology, 34:2, 120-129, DOI: 10.1080/08880018.2017.1323985
You can read the full, open access article here.
PanCareLIFE researchers at the University of Bern have just published a new paper ‘Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study’, funded in part by PanCareLIFE. You can read the full, open access article here.
PanCareLIFE researchers at EMC, VUmc, AMC, PMC and UKM have published ‘Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study’, funded in part by PanCareLIFE.
European Journal of Cancer (2016) 69: 77, DOI: 10.1016/j.ejca.2016.09.023
Our Danish colleagues from KB are co-authors on the publication ‘Gastrointestinal and liver disease in Adult Life After Childhood Cancer in Scandinavia: A population-based cohort study’ in the International Journal of Cancer.
Our publication ‘Fertility preservation in children, adolescents, and young adults with cancer: Quality of clinical practice guidelines and variations in recommendations’ has been published in Cancer (2016 Jul 15;122(14):2216-23. doi: 10.1002/cncr.30047.).
You can read the full, open access article here.
The Danish Cancer Society Research Center, project partner in PanCareLIFE, have recently published the first large-scale study of the lifetime risk for autoimmune diseases after childhood cancer, with risk estimates for a broad range of well-defined, medically verified autoimmune diseases. in Annals of the Rheumatic Diseases (Autoimmune diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS) – Ann Rheum Dis. 2015 Nov 10. pii: annrheumdis-2015-207659).
You can read the press release here.
The first author Anna S. Holmqvist, MD, PhD from Lund in Sweden has also been interviewed for a news story in The Lancet Oncology.
See our Publications page for other PanCareLIFE related publications.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.